Vaccines
RSSArticles
-
HPV Vaccination Rate Needs Improvement
The prevalence of HPV infections and their sequelae remain high, although this is a problem that is preventable with available vaccines.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
In a study of human papillomavirus (HPV) vaccination, researchers evaluated cancer protection over up to 11 years of follow-up. During this time, the authors noted 100% vaccine efficacy at preventing HPV-associated cancers.
-
Human Papillomavirus Infections: We Need to Improve Vaccination Rates
The prevalence of human papillomavirus infections and their sequelae remain high, although this is a problem that is preventable with available vaccines.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
The authors of this long-term follow-up study of three cluster-randomized trials of human papillomavirus (HPV) vaccination evaluated cancer protection over up to 11 years of follow-up. During this time, 17 HPV-positive cancers were identified in the unvaccinated group, and zero were identified in the vaccinated group, indicating 100% vaccine efficacy at preventing HPV-associated cancers.
-
Who Can Get the Janssen/J&J (Non-mRNA) COVID-19 Vaccine Now?
The Food and Drug Administration recently limited the use of the Janssen COVID-19 vaccine.
-
Too Many Antibiotics May Affect Vaccine Response Among Infants, Toddlers
Remain cautious about overprescribing antibiotics.
-
COVID-19 Vaccine and the Menstrual Cycle
In a retrospective cohort analysis of prospectively tracked menstrual cycle data from the smartphone application “Natural Cycles,” the COVID-19 vaccine was associated with a less than one day change in menstrual cycle length and no change in menses length.
-
ACC Publishes Guidance on Managing Cardiovascular Ailments Post-COVID Infection
Expert panel created document to help clinicians manage patients with myocarditis and other long COVID problems associated with SARS-CoV-2.
-
Booster Doses Effective Against Omicron
While vaccination provides protection against infection with omicron variant of SARS-CoV-2, high level protection from a need for hospitalization requires a booster dose.
-
Multiple Sclerosis and Immune Response to COVID-19 Vaccination
A large group of patients with multiple sclerosis taking various disease-modifying therapies did not respond uniformly to COVID-19 vaccination.